clinical development comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Ricin is very toxic if inhaled, injected, or ingested. It can also be toxic if dust contacts the eyes or if it is absorbed through damaged skin. It acts as a toxin by inhibiting protein synthesis. Ricin is resistant, but not impervious, to digestion by peptidases. By ingestion, the pathology of ricin is largely restricted to the gastrointestinal tract, where it may cause mucosal injuries. With appropriate treatment, most patients will make a good recovery.
== Discovery of the proton == Back in 1815, William Prout observed that the atomic weights of the known elements were multiples of hydrogen's atomic weight, so he hypothesized that all atoms are agglomerations of hydrogen, a particle which he dubbed "the protyle". Prout's hypothesis was put into doubt when some elements were found to deviate from this pattern—e.g. chlorine atoms on average weigh 35.45 daltons—but when isotopes were discovered in 1913, Prout's observation gained renewed attention. In 1917 Rutherford bombarded nitrogen gas with alpha particles and observed hydrogen ions being emitted from the gas. Rutherford concluded that the alpha particles struck the nuclei of the nitrogen atoms, causing hydrogen ions to split off. These observations led Rutherford to conclude that the hydrogen nucleus was a singular particle with a positive charge equal to that of the electron's negative charge. The name "proton" was suggested by Rutherford at an informal meeting of fellow physicists in Cardiff in 1920. The charge number of an atomic nucleus was found to be equal to the element's ordinal position on the periodic table. The nuclear charge number thus provided a simple and clear-cut way of distinguishing the chemical elements from each other, as opposed to Lavoisier's classic definition of a chemical element being a substance that cannot be broken down into simpler substances by chemical reactions. The charge number or proton number was thereafter referred to as the atomic number of the element.
== Archaeology and paleontology == In archaeology, the Maillard process occurs when bodies are preserved in peat bogs. The acidic peat environment causes a tanning or browning of skin tones and can turn hair to a red or ginger tone. The chemical mechanism is the same as in the browning of food, but it develops slowly over time due to the acidic action on the bog body. It is typically seen on Iron Age bodies and is the result of the interaction of anaerobic, acidic, and cold (typically 4 °C (39 °F)) sphagnum acid on the polysaccharides. The Maillard reaction also contributes to the preservation of paleofeces.
== Applications == If an oscillating U-tube is filled with water and pistons are placed at each end, pressure exerted by the left piston will be transmitted throughout the liquid and against the bottom of the right piston. (The pistons are simply "plugs" that can slide freely but snugly inside the tube.) The pressure that the left piston exerts against the water will be exactly equal to the pressure the water exerts against the right piston
Antigen-naive T cells expand and differentiate into memory and effector T cells after they encounter their cognate antigen within the context of an MHC molecule on the surface of a professional antigen presenting cell (e.g. a dendritic cell). Appropriate co-stimulation must be present at the time of antigen encounter for this process to occur. Historically, memory T cells were thought to belong to either the effector or central memory subtypes, each with their own distinguishing set of cell surface markers (see below). Subsequently, numerous new populations of memory T cells were discovered including tissue-resident memory T (Trm) cells, stem memory TSCM cells, and virtual memory T cells. The single unifying theme for all memory T cell subtypes is that they are long-lived and can quickly expand to large numbers of effector T cells upon re-exposure to their cognate antigen. By this mechanism they provide the immune system with "memory" against previously encountered pathogens. Memory T cells may be either CD4+ or CD8+ and usually express CD45RO. Memory T cell subtypes:
Sources: en.wikipedia.org
== Signs and symptoms == Buried bumper syndrome may be asymptomatic, especially early in the course. Dysfunction of the tube occurs commonly, including leakage around the insertion site, inability to administer feedings or fluids, or need for more pressure when giving feeds. Buried bumper syndrome may cause abdominal pain or swelling (erythema) at the site of insertion of the PEG tube. Less commonly, buried bumper syndrome may also be complicated by acute infectious illness (sepsis), abscess formation, gastrointestinal bleeding or peritonitis. In some cases, the internal bumper may be felt by palpating the abdomen. Inspection of the tube typically reveals an inability to easily rotate the tube.
Austin no-showed the Raw after WrestleMania and took a week-long break without the company's consent, citing exhaustion. Austin returned on the April 1 episode of Raw, the first of the new "brand extension" era. The show was centered around which show he would sign with, and he ultimately chose Raw. Austin entered a feud with The Undertaker that resulted in a number-one contender's match for the Undisputed WWF Championship at Backlash on April 21, which Austin lost. In a May interview on WWE's internet program, Byte This!, Austin stunned the company and fans by launching a verbal attack on the direction the company was heading in and slated the creative team for not using him the way he felt they previously did. The WWE rehired Eddie Guerrero for Austin to feud with, while also prepping Austin for a feud with Brock Lesnar. However, Austin balked at the proposition that he lose a King of the Ring qualifying match on Raw to Lesnar, and ultimately walked out of the company. Austin later explained that he thought hot-shotting a rookie made Austin look weak, and airing the match on free television with no build-up did not give Lesnar a proper stage for such a big win over a star of Austin's magnitude. Further fanning the flames among Austin's growing number of detractors was a well-publicized domestic dispute incident between Austin and his wife Debra (see below). After Austin again no-showed the June 10 episode of Raw, his storylines were immediately dropped.
Class 350: 350 °F (176.7 °C) at 100% relative humidity for paper records, which keeps the contents below the charring point of 420 °F (215.6 °C); Class 150: 150 °F (65.6 °C) at 85% relative humidity for photographic, magnetic, or similar non-paper records; Class 125: 125 °F (51.7 °C) at 80% relative humidity for the more heat-sensitive floppy disks. A safe rated UL Class 150 or UL Class 125 and intended to hold only computer media is sometimes called a media safe, and Class 125 units are also known as data safes. NFPA 232 requires that the vault door be a listed vault door with a fire-resistive rating that meets or exceeds that of the vault walls. Wall penetrations must be sealed to prevent the intrusion of smoke, heat, flame, or water, with a listed fire-rated through-penetration assembly for general penetrations and listed fire-rated material for penetrations for sprinkler piping, electric lighting, conduit, and power-limited circuits, in each case with a rating that meets or exceeds that of the vault. Ventilation openings must be as small as possible, protected to maintain the required rating of the wall, and fitted with smoke dampers activated by automatic sensing devices. Paper water-damaged in a fire can be remediated by vacuum freeze-drying, in which water is sublimed from the liquid state to a vapor, causing less ink bleeding and planar distortion than air or desiccant drying.
==== MeSH D13.570.685 – pyrimidine nucleosides ==== MeSH D13.570.685.245 – cytidine MeSH D13.570.685.245.217 – azacitidine MeSH D13.570.685.245.453 – cytarabine MeSH D13.570.685.245.453.050 – ancitabine MeSH D13.570.685.245.500 – deoxycytidine MeSH D13.570.685.245.500.250 – bromodeoxycytidine MeSH D13.570.685.245.500.950 – zalcitabine MeSH D13.570.685.245.500.950.500 – lamivudine MeSH D13.570.685.350 – formycins MeSH D13.570.685.350.200 – coformycin MeSH D13.570.685.350.200.700 – pentostatin MeSH D13.570.685.705 – thymidine MeSH D13.570.685.705.875 – stavudine MeSH D13.570.685.705.900 – trifluridine MeSH D13.570.685.705.950 – zidovudine MeSH D13.570.685.725 – tunicamycin MeSH D13.570.685.852 – uridine MeSH D13.570.685.852.150 – arabinofuranosyluracil MeSH D13.570.685.852.176 – azauridine MeSH D13.570.685.852.250 – 3-deazauridine MeSH D13.570.685.852.300 – deoxyuridine MeSH D13.570.685.852.300.150 – bromodeoxyuridine MeSH D13.570.685.852.300.350 – floxuridine MeSH D13.570.685.852.300.400 – idoxuridine MeSH D13.570.685.852.628 – pseudouridine MeSH D13.570.685.852.800 – tetrahydrouridine MeSH D13.570.685.852.829 – thiouridine
Sources: en.wikipedia.org
== Comparison to other detectors == The conversion efficiency of ions to photons by an IPD is as good as, or better than, the conversion efficiency of ions to electrons by a multichannel plate detector. Ion-to-photon detectors may also detect ions with a mass of up to around 20,000 Da, better than microchannel plates. However, the resolution of the mass spectrum from an IPD equipped spectrometer is slightly lower. The noise in the spectrum, which may come from unfocused, slow speed ions, is also slightly higher.
Half-Life 2: Episode Two received an average score of 90.68% based on 22 reviews on the review aggregator GameRankings. On Metacritic, it has an average score of 90 out of 100 based on 21 reviews, indicating "universal acclaim". As part of The Orange Box compilation, Episode Two shared with Portal and Team Fortress 2 in winning "Computer Game of the Year" at the 11th Annual Interactive Achievement Awards. Dan Adams of IGN rated the game 9.4 out of 10 and praised its improved visuals and expansive environments, but cited the short six-hour length as a drawback. He said: "Any way you look at it, Episode Two stands out, even among the Half-Life series, as something special ... a burly experience packed into roughly six hours or so that offers up all the diversity, level design, and thoughtful gameplay we've known while making sure to propel the story forward and leave us wanting more." Bit-tech awarded the game a ten out of ten score, citing approval of how the story turns and the introduction of side stories and new characters. 1UP.com said that it was "vivid, emotionally engaging, and virtually unsurpassed". PC Gamer UK felt that Episode Two was "the most sumptuous chapter of the Half-Life saga, and by a country mile". The New York Times enjoyed the gameplay, saying that battles "often require as much ingenuity as they do fast reflexes". Computer and Video Games said that, although the Source engine was dated, the "wonderful art design and the odd bit of technical spit-shine ensure that Episode Two [...] doesn't lose any of its wow factor".
Radical reactions that cleave C–H bonds. Ion exchange that of tertiary and aromatic hydrogen. Enolizations that activate hydrogens on ketone alpha carbons. Stereochemical exchange that causes stereochemical inversion. Constitutional exchange like methyl shifts, double bond migrations and carbon backbone rearrangements. Detailed kinetics of these reactions have not been determined. However, it is known that clay minerals catalyze ionic hydrogen exchange faster than other minerals. Thus hydrocarbons formed in clastic environments exchange more than those in carbonate settings. Aromatic and tertiary hydrogen also have greater exchange rates than primary hydrogen. This is due to the increasing stability of associated carbocations. Primary carbocations are considered too unstable to exist and have never been isolated in an FT-ICR spectrometer. On the other hand, tertiary carbocations are relatively stable and are often intermediates in organic chemistry reactions. This stability, which increases the likelihood of proton loss, is due to the electron donation of nearby carbon atoms. Resonance and nearby lone pairs can also stabilize carbocations via electron donation. Aromatic carbons are thus relatively easy to exchange. Many of these reactions have a strong temperature dependence; higher temperature typically accelerates exchange. However, different mechanisms may prevail at each temperature window. Ion exchange, for example, is most significant at low temperature.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.